Human Immunodeficiency Virus and the Central Nervous System

Seminars in Pediatric Neurology

Volumn 19, Issue 3, 2012, Pages 119-123

  Mirza, Ayesha ^a   Rathore, Mobeen H ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b WOLFSON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; EFAVIRENZ; FOSAMPRENAVIR; LOPINAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG PENETRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VIRUS ENCEPHALITIS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; COGNITION DISORDERS; HIV; HIV INFECTIONS; HUMANS;

EID: 84865185522     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2012.02.007     Document Type: Review

References (30)

1. Grovit-Ferbas K., Harris-White M.E. Thinking about HIV: The intersection of virus, neuroinflammation and cognitive dysfunction. Immunol Res 2010, 48:40-58.
2. González-Scarano F., Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005, 5:69-81.
3. An S.F., Groves M., Gray F., et al. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol 1999, 58:1156-1162.
4. Chaudhuri A., Yang B., Gendelman H.E., et al. STAT1 signaling modulates HIV-1 induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 2008, 111:2062-2072.
5. Kanmogne G.D., Schall K., Leibhart J., et al. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across the blood-brain barrier: Implication for viral neuropathogenesis. J Cereb Blood Flow Metab 2007, 27:123-134.
6. Sorce S., Myburgh R., Krause K.H. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 2011, 93:297-311.
7. Ellis R.J., Calero P., Stockin M.D. HIV infection and the CNS: A primer. Neuropsychol Rev 2009, 19:144-151.
8. Clements J.E., Li M., Gama L., et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: A model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 2005, 11:180-189.
9. Vissers M., Stelma F.F., Koopmans P.P. Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?. Clin Neurol 2010, 49:231-238.
10. Smit T.K., Brew B.J., Tourtellotte W., et al. Independent evolution of human immunodeficiency virus drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004, 78:10133-10148.
11. Wong J.K., Ignacio C.C., Torriani F., et al. In vivo compartmentalization of human immunodeficiency virus: Evidence from the examination of pol sequences from autopsy tissues. J Virol 1997, 71:2059-2071.
12. Antinori A., Cingolani A., Giancola M.L., et al. Clinical implications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis 2003, 106(suppl):41-44.
13. Christo P.P., Greco D.B., Aleixo A.W., et al. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis 2007, 21:147.
14. Staprans S., Marlowe N., Glidden D., et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: Evidence for variable compartmentalization of infection. AIDS 1999, 13:1051-1061.
15. Lambotte O., Deiva K., Tardieu M. HIV persistence, viral reservoir and the central nervous system in the HAART era. Brain Pathol 2003, 13:95-103.
16. Clifford D.B. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008, 16. 94-17.
17. Brew B.J., Pemberton L., Blennow K., et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005, 65:1490-1492.
18. Clifford D.B., Fagan A.M., Holtzman D.M., et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009, 73:1982-1987.
19. Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol 2009, 4:213-217.
20. Xu J., Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: A foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 2009, 4:200-212.
21. Lindl K.A., Marks D.R., Kolson D.L., et al. HIV associated neurocognitive disorder: Pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010, 5:294-309.
22. Heaton R.K., Franklin D.R., Ellis R.J., et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol 2011, 17:3-16.
23. Robertson K., Fiscus S., Kapoor C., et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol 1998, 4:90-94.
24. Epstein L.G., Sharer L.R., Oleske J.M., et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 1986, 78:678-687.
25. Chase C., Ware J., Hittelman J., et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics 2000, 106:E25.
26. Williams P.L., Marino M., Malee K., et al. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics 2010, 125:e250-e260. 219C Team.
27. Patel K., Ming X., Williams P.L., et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009, 23:1893-1901. International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team.
28. Perez-Valero I., Bayon C., Cambron I., et al. Protease inhibitor monotherapy and the CNS: Peace of mind?. J Antimicrob Chemother 2011, 66:1954-1962.
29. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011, 19:137-142.
30. Bogoch I.I., Davis B.T., Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 2011, 63:236-239.